A U.S. House committee alleged Tuesday that AbbVie gamed the federal orphan drug program to boost profits for its anti-inflammatory drug Humira—by far, the top-selling medicine in the United States.
Four types of hospitals that participate in the 340B program are unable to purchase Humira and other drugs with orphan disease designations at reduced 340B prices. Legislation has been re-introduced to partially lift the ban.
A U.S. House committee alleged Tuesday that AbbVie gamed the federal orphan drug program to boost profits for its anti-inflammatory drug Humira—by far, the top-selling medicine in the United States.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
